GlassScriptPhysician profile
Steven A Nielsen
NPI 1477554251
$2,175.51
in general payments reported to CMS, 2019-2025
20 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $52.12 · 2021: $143 · 2022: $296 · 2023: $530 · 2024: $788 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $401.25 | 2024 | Iheezo |
| Glaukos Corporation | $387.51 | 2021-2024 | Photrexa, Ce-Marked Kxla System, Kxl1b-Ce-Marked Kxlsystem |
| Alcon Vision LLC | $218.88 | 2019-2025 | Eysuvis, Simbrinza, Rocklatan |
| Abbvie INC. | $212.66 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $206.53 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $126.02 | 2019-2024 | Tecnis Iol |
| Oyster Point Pharma, INC. | $110.99 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $69.18 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $56.99 | 2019 | |
| Rayner Intraocular Lenses Limited | $56.50 | 2022-2023 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Rxsight INC | $48.99 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $48.72 | 2019-2024 | |
| Shire North American Group INC | $44.56 | 2019 | |
| Sight Sciences, INC. | $38.52 | 2022-2024 | Omni Surgical System |
| Kala Pharmaceuticals, INC. | $35.50 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.33 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $25.79 | 2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $23.21 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.73 | 2020 | |
| Ocular Therapeutix, INC. | $13.65 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Nielsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.